Christel Müller

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes

F. Solé, K. Götze, N. Kröger, 2019, Genes, chromosomes & cancer.

polyclonal hematopoiesis in the majority patients in cytogenetic remission to imatinib but restoration of cells in some CML - Emergence of clonal cytogenetic abnormalities in Ph

K. Krohn, M. Deininger, H. Al-Ali, 2012 .

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

K. Krohn, M. Deininger, D. Niederwieser, 2003, Blood.

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

B. Druker, M. Heinrich, D. Niederwieser, 2004, The hematology journal : the official journal of the European Haematology Association.

No evidence for persistence of BCR-ABL–positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia

M. Deininger, D. Niederwieser, R. Krahl, 2000 .

The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients.

D. Niederwieser, R. Krahl, Christel Müller, 2002, Cancer genetics and cytogenetics.

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

K. Krohn, M. Deininger, D. Niederwieser, 2003, Blood.